Protein design platform supports discovery partnerships and asset licensing for customized antibodies, gene editors, and enzymes.

Protein language-model family generates new proteins and redesigns domains, with model API access offered through an early-access program.

AI-designed Cas9-like gene editor and guide RNA are available for research and licensed commercial use; they are not approved therapies.

Research web tool predicts and customizes CRISPR-Cas targeting preferences, with access offered for noncommercial use.

Announced investigational collection of AI-designed antibodies targeting twenty drug targets, with licensing release under development.